Do you want to read an article? Please log in or register.
Metastatic castration-resistant prostate cancer: Clinical data, new treatment options and therapy monitoring
Genitourinary Cancer
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
RECOMMENDED
Genitourinary Cancer
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era
Cancer Treat Rev.
Tucci M, Caffo O, Buttigliero C, Cavaliere C, D'aniello C, Di Maio M, Kinspergher S, Maines F, Rizzo M, Rossetti S, Veccia A, Scagliotti GV, Facchini G
doi: 10.1016/j.ctrv.2019.01.002.
Genitourinary Cancer
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
Lancet Oncol.
Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC; Prostate Cancer Challenge DREAM Community.
COMMENTED
Genitourinary Cancer
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Prostate.
Shore ND, Drake CG, Lin DW, Ryan CJ, Stratton KL, Dunshee C, Karsh LI, Kaul S, Kernen K, Pieczonka C, Sieber P, Stewart C, Williams M, Concepcion RS
doi: 10.1002/pros.24053.
Genitourinary CancerRadio-Oncology
Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group
Eur Urol Oncol.
O'Sullivan JM, Carles J, Cathomas R, Gomez-Iturriaga A, Heinrich D, Kramer G, Ost P, van Oort I, Tombal B
doi: 10.1016/j.euo.2019.02.007.
Genitourinary Cancer
Novel Treatment Options in the Management of Metastatic Castration-naïve Prostate Cancer; Which Treatment Modality to Choose?
Ann Oncol.
Belderbos BPS, de Wit R, Lolkema MPJ, Mathijssen RHJ, van Soest RJ
doi: 10.1093/annonc/mdz210.
Genitourinary Cancer
Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry
Clin Genitourin Cancer.
Stenner F, Rothschild SI, Betticher D, Caspar C, Morant R, Popescu R, Rauch D, Huber U, Zenhäusern R, Rentsch C, Cathomas R
doi: 10.1016/j.clgc.2017.08.003.
Genitourinary Cancer
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database
Eur J Cancer.
Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthélémy P, Sella A, Fizazi K, Ferrero JM, Laguerre B, Thibault C, Hans S, Oudard S
doi: 10.1016/j.ejca.2019.10.030.
Genitourinary Cancer
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
J Clin Oncol.
Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O
doi: 10.1200/JCO.2016.72.1068.